Southwest Oncology Group researchers have found that starting Keytruda (pembrolizumab) before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
